2007-12-29 Guangzhou
Guangdong Jiaying Pharmaceutical Co. Ltd. recently held three A-share IPO roadshows targeting institutional investors in Shenzhen, Shanghai and Beijing, respectively. Huang Libing, General Manager of Guangdong Jiaying Pharmaceutical, said the company aims to become China’s leading provider of traditional Chinese patent medicines specializing in drugs for treatment of sore throat and influenza.
The drug maker was established as a result of reorganization of Guangdong Meizhou Jiaying Pharmaceutical, and is primarily involved in traditional Chinese medicines for faucitis, cold, gastroenteritis and nutritional supplements.
Guangdong Jiaying Pharmaceutical plans to issue 20.5 million new shares, which account for 25 percent of the total share capital following the IPO. The company hopes to raise approximately RMB 175 million (approx. US$22.4 million) through the IPO, and the funds raised will be used for expanding production capacity of its traditional Chinese medicines including Shuangliao Houfeng Powder as well as Shuangliao Houfeng Tablet.
Guangdong Jiaying Pharmaceutical has established marketing and distribution centers in 29 provinces and cities across China. The company will endeavour to increase the market share of its Shuangliao Houfeng San Powder and Tablet in the domestic market of sore throat remedies to approximately 2% over the next two to three years, according to Huang Libing.